Mast Therapeutics Inc (NYSEMKT:MSTX) announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires’ lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension. Mast Therapeutics Inc (NYSEMKT:MSTX) stock performance was 12.12% in last session and finished the day at $0.828. Traded volume was 21,508,860 million shares in the last session and the average volume of the stock remained 4.08 million shares. The beta of the stock remained 1.98. Mast Therapeutics Inc (NYSEMKT:MSTX) insider ownership is 1.00%.

Geron Corporation (NASDAQ:GERN)’s shares declined 3.07% to $2.21. The company on Mar. 20 said the U.S. Food and Drug Administration ordered a halt to new patient enrollments in an early-stage trial of its blood cancer drug, imetelstat, over concerns about liver damage.Geron Corporation (NASDAQ:GERN) dropped -1.75percent to $2.24yesterday on volume of 6.45million shares. The intra-day range of the stock was $2.13 to $2.38. Geron Corporation (NASDAQ:GERN) has a market capitalization of $351.45million.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013. The company said its fourth quarter revenues totaled $6.5 million, including $2.4 million in BELVIQ product revenue, of which $2.3 million represented 31.5% of Eisai’s net product sales and $0.1 million related to redemptions of the 15-day free trial voucher. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock on Mar20, 2014 reported a decrease of -3.15% to the closing price of $6.31. Its fifty two weeks range is $4.05 -$9.25. The total market capitalization recorded $1.38 billion. The overall volume in the last trading session was 7,096,757 million shares. In its share capital, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has 218.64 million outstanding shares.

MLV analyst Graig Suvannavejh, on MannKind Corporation (NASDAQ:MNKD) and the prospects for the April 1 FDA advisory panel reviewing the inhaled insulin device Afrezza. On Thursday, shares of MannKind Corporation (NASDAQ:MNKD) advanced 3.51% to close the day at $5.89. Company’s monthly performance is recorded as -0.34%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 19.23%.